Fibrosis predicts post-surgical risk in aortic stenosis, reinforcing its role in guiding treatment decisions for both sexes.

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Varanasi: A team of skilled doctors at the Cardiology department at the Institute of Medical Sciences (IMS), Banaras Hindu ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides ...

Discover how recent advancements in cardiovascular medicine, including TAVI and TEER, are revolutionizing heart disease ...

The webcasts of the TD Cowen and Barclays fireside chats can be accessed by visiting the Investor Center section of the Company’s website at ...